Any current/future new fundraising through debt or equity?

There was a suggestion for a smaller rights issue of INR 30-40 crores to improve liquidity; this has been considered internally by the team. No explicit confirmation of immediate fundraising via debt or equity was provided during the call. Management indicated no need to defer acquisitions or capital expenditures, implying sufficient current liquidity and no urgent requirement for fresh funding. Planned capex is limited to ongoing projects (Atlas Chhatral and ATC), totaling around INR 40 crores, after which the company intends to enter a consolidation phase lasting at least a year and a

Any current/future capex/capital investment/strategic investment?

Current capex includes INR 70 crores investment in the Chhatral plant aimed at backward integration for the API business, expected to achieve around INR 200 crores external sales at peak. Additional capex of about INR 30 crores is planned for doubling AZO dye capacities, particularly yellow, adding approx. 1,200 tons capacity with INR 10-14 crores capex; expansion expected to complete within 8-9 months. No new capital expenditure planned beyond the two ongoing projects (Atlas Chhatral and ATC) for at least one to two years; company will enter a consolidation phase post-completion. Plans to inv

Future growth expectations in sales/revenue/volumes?

The Blue business is expected to remain a cash cow with no major capex; moderate growth around 10% is unlikely. Peak capacity turnover around INR 800 crores group-wide is possible, with expected revenue between INR 700-750 crores in 2-3 years after ramp-up. Chhatral facility external sales expected to reach INR 200 crores at peak. Dahej AZO dyes segment targeting to increase from INR ~45 crores to ~INR 90 crores in FY24, driven mainly by domestic sales and expanding yellow pigment capacity. Yellow pigments expected to dominate 70-75% of turnover for next 3 years, with capacity expansio

Future growth expectations in earnings/operating earnings/profits/EPS?

The worst quarters are behind, with Q1 FY24 (April-June) expected better than Q4 FY23; no similar downturn anticipated again. Business is bottoming out with global supply chain inventory at lows; demand revival expected leading to recovery of cash cow (Blue business). Peak capacity turnover estimated around INR 800 crores on group basis, with more realistic INR 700-750 crores achievable, maintaining 15-17% EBITDA margins long term. AZO segment expected to grow from ~INR 41 crores to INR 90 crores in FY24, driven by increased volumes and new shifts. Chhatral plant to contribute INR 200

Current/ Expected Orderbook/ Pending Orders?

No explicit mention of current or expected orderbook or pending orders is provided on page 28 or related pages. However, references indicate ongoing customer approvals and business ramp-ups: - European and U.S. customers are in testing phases; it may take about six months for some to start orders (Page 27). - Revival and increased demand expected from European customers such as Sun, Siegwerk, and Clariant (Page 15-18). - Current business from European customers is minimal except for TTC, with around 90% sales in India for AZO dyes segment (Page 20). The company is confident of improved r

Asahi SongwonQ4 FY23

Asahi Songwon Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹370.35P/E: 12.5Market Cap: ₹437 Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The Blue business is expected to remain a cash cow with no major capex; moderate growth around 10% is unlikely.
Peak capacity turnover around INR 800 crores group-wide is possible, with expected revenue between INR 700-750 crores in 2-3 years after ramp-up.
Chhatral facility external sales expected to reach INR 200 crores at peak.
Dahej AZO dyes segment targeting to increase from INR ~45 crores to ~INR 90 crores in FY24, driven mainly by domestic sales and expanding yellow pigment capacity.
Yellow pigments expected to dominate 70-75% of turnover for next 3 years, with capacity expansion underway.
New small molecule API products (2-4) to be launched gradually; however, these won't significantly impact top-line immediately.
Pregabalin remains key API product with plans for backward integration and approvals for export markets to improve margins and utilization over 3 years.
Overall target is 15-17% EBITDA margins on normalized peak revenues.

Margin guidance

Category 3

The worst quarters are behind, with Q1 FY24 (April-June) expected better than Q4 FY23; no similar downturn anticipated again.
Business is bottoming out with global supply chain inventory at lows; demand revival expected leading to recovery of cash cow (Blue business).
Peak capacity turnover estimated around INR 800 crores on group basis, with more realistic INR 700-750 crores achievable, maintaining 15-17% EBITDA margins long term.
AZO segment expected to grow from ~INR 41 crores to INR 90 crores in FY24, driven by increased volumes and new shifts.
Chhatral plant to contribute INR 200 crores top-line (external sales) at peak, supporting backward integration and margin improvement in API segment.
API business (dominated by pregabalin) expected to consolidate and grow via approvals for regulated markets over 3-5 years, introducing higher value products.
Overall, confidence expressed for revenue and profit improvement in coming quarters and years, aiming for INR 1,000 crores turnover in medium term.

See what Asahi Songwon management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

There was a suggestion for a smaller rights issue of INR 30-40 crores to improve liquidity; this has been considered internally by the team.
No explicit confirmation of immediate fundraising via debt or equity was provided during the call.
Management indicated no need to defer acquisitions or capital expenditures, implying sufficient current liquidity and no urgent requirement for fresh funding.
Planned capex is limited to ongoing projects (Atlas Chhatral and ATC), totaling around INR 40 crores, after which the company intends to enter a consolidation phase lasting at least a year and a half with no new capex.
Management expects to de-lever the balance sheet in a planned fashion post peak capex.
No mention of new large-scale debt raising; existing debt peaks at INR 210 crores and is to be reduced afterward.

Order book

No explicit mention of current or expected orderbook or pending orders is provided on page 28 or related pages.
However, references indicate ongoing customer approvals and business ramp-ups:
- European and U.S. customers are in testing phases; it may take about six months for some to start orders (Page 27).
- Revival and increased demand expected from European customers such as Sun, Siegwerk, and Clariant (Page 15-18).
- Current business from European customers is minimal except for TTC, with around 90% sales in India for AZO dyes segment (Page 20).
The company is confident of improved results in coming quarters and expects consolidation phase by second half of 2024 (Page 28).
New product launches and expansions (Chhatral plant, Dahej yellow line expansion) will support future order growth (Pages 19-26).

See what Asahi Songwon management said on order book — free account, 30 seconds.

Capex plans

Yes

Current capex includes INR 70 crores investment in the Chhatral plant aimed at backward integration for the API business, expected to achieve around INR 200 crores external sales at peak.
Additional capex of about INR 30 crores is planned for doubling AZO dye capacities, particularly yellow, adding approx. 1,200 tons capacity with INR 10-14 crores capex; expansion expected to complete within 8-9 months.
No new capital expenditure planned beyond the two ongoing projects (Atlas Chhatral and ATC) for at least one to two years; company will enter a consolidation phase post-completion.
Plans to invest in renewable energy (wind and solar) are mentioned but no significant capex is planned currently for these.
Management is considering a smaller rights issue (INR 30-40 crores) to boost liquidity.
Focus over the next 3-5 years is on ramping up multiple products at various locations, aiming for INR 1,000 crores revenue goal.

Track Asahi Songwon — get its next earnings analysis in your feed

How does Asahi Songwon rank vs peers in ?

Pro feature

ThisAsahi Songwon

Rev 3Mar 3

See where Asahi Songwon sits in See which companies these are, and every other name in the sector.Open rankings

What Asahi Songwon's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Asahi Songwon Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Continue your research

What Asahi Songwon's management said in earlier quarters